BUZZ-Monte Rosa Therapeutics dips after $200 mln equity offering launched
I'm PortAI, I can summarize articles.
Monte Rosa Therapeuticsshares fell 1.1% to $23.03 premarket following a $200 million equity offering. The offering includes stock and pre-funded warrants. The company's shares surged 45% to a four-year high of $23.28 after announcing positive early-stage trial results for its heart drug, MRT-8102. Proceeds will fund MRT-8102's development for chronic inflammatory diseases and the QuEENTM platform. Analysts remain bullish, with a median price target of $30, up from $18 a month ago.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments